Cargando…
Development of COVID-19 vaccine using a dual Toll-like receptor ligand liposome adjuvant
We developed a SARS-CoV-2 spike subunit vaccine formulation containing dual TLR ligand liposome adjuvant. The vaccine-induced robust systemic neutralizing antibodies and completely protected mice from a lethal challenge. Two immunizations protected against lung injury and cleared the virus from lung...
Autores principales: | Abhyankar, Mayuresh M., Mann, Barbara J., Sturek, Jeffrey M., Brovero, Savannah, Moreau, G. Brett, Sengar, Anjali, Richardson, Crystal M., Agah, Sayeh, Pomés, Anna, Kasson, Peter M., Tomai, Mark A., Fox, Christopher B., Petri, William A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8602664/ https://www.ncbi.nlm.nih.gov/pubmed/34795290 http://dx.doi.org/10.1038/s41541-021-00399-0 |
Ejemplares similares
-
SARS-CoV-2 full length spike protein for COVID-19 vaccine development and diagnostic testing
por: Richardson, Crystal, et al.
Publicado: (2021) -
Understanding Activation and Inhibition of SARS-CoV-2 Viral Entry with Single-Virus Microscopy
por: Sengar, Anjali, et al.
Publicado: (2021) -
Improved survival of SARS COV-2-infected K18-hACE2 mice treated with adenosine A(2A)R agonist()
por: Mann, Barbara J., et al.
Publicado: (2023) -
Adjuvant composition and delivery route shape immune response quality and protective efficacy of a recombinant vaccine for Entamoeba histolytica
por: Abhyankar, Mayuresh M., et al.
Publicado: (2018) -
Elucidating coronavirus fusion mechanisms
por: Hess, Tobin, et al.
Publicado: (2023)